Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Financial Officer

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and dia...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-09-28	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-09-28	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-06-21	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-06-20	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-06-09	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-09-14	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-06-16	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2022-05-31	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2022-05-27	Premium	bought	Premium	Premium	Premium	Chief Executive Officer

RNAZ - TransCode Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for RNAZ